Otilonium Bromide: Mechanism, Uses & Limits

Executive Summary: Otilonium Bromide is described as a quaternary ammonium antimuscarinic agent that modulates muscarinic acetylcholine receptor signaling; the APExBIO product information identifies its chemical name as diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide. The reported molecular weight is 563.57 g/mol, and the stated purity is at least 98% according to the product page. The page reports solubility of at least 28.18 mg/mL in DMSO, at least 55.8 mg/mL in water, and at least 91 mg/mL in ethanol; the cited page does not specify the temperature or pH for these values. The 2021 reference study investigated SARS-CoV-2 NSP15 with virtual screening and molecular-dynamics simulations, not Otilonium Bromide receptor pharmacology or antiviral efficacy (Vijayan and Gourinath, 2021).

Biological Rationale

Acetylcholine is a signaling molecule used by neuronal and non-neuronal systems. Muscarinic receptors translate acetylcholine binding into cellular responses through receptor-linked signaling processes. An antimuscarinic compound provides a pharmacological way to reduce or dissect those responses in a defined assay.

Otilonium Bromide is therefore useful when the experimental question concerns muscarinic control of contractility, excitability, secretion, or related cholinergic outputs. In smooth muscle pharmacology, the compound can help distinguish acetylcholine-driven activity from receptor-independent effects. In neuroscience receptor modulation, it can serve as a tool compound for testing whether an observed phenotype depends on muscarinic signaling.

The phrase acetylcholine receptor inhibitor requires precision. AChR can refer broadly to nicotinic and muscarinic acetylcholine receptors. Otilonium Bromide should be described primarily as an antimuscarinic agent rather than as a nonselective blocker of every AChR class. This distinction is essential when interpreting calcium, contractility, membrane-potential, or neurotransmission readouts.

Mechanism of Action of Otilonium Bromide

The product dossier assigns Otilonium Bromide an antimuscarinic mechanism. Operationally, the compound is used to inhibit muscarinic acetylcholine receptor-mediated responses and thereby modulate a cholinergic signaling pathway. The intended experimental consequence is reduced signaling through the receptor population engaged by the assay stimulus.

The molecule is supplied as a bromide salt with a quaternary ammonium center. Its chemical identity and salt form should be recorded in the methods section because counterion and formulation can affect stock preparation. The product page reports a molecular weight of 563.57 g/mol, which should be used when converting mass concentrations into molar concentrations.

Mechanistic attribution requires controls. A vehicle control should match the DMSO content of treated wells. A receptor-stimulation control should establish the baseline response before antagonist exposure. A concentration-response design should test whether the phenotype changes consistently with increasing compound exposure. These are workflow recommendations, not quantitative claims about an unreported potency value.

Evidence & Benchmarks

The available evidence separates product characterization from the supplied peer-reviewed antiviral reference. The product page supports formulation and handling facts. The DOI-linked study supports conclusions about SARS-CoV-2 NSP15 screening. It does not validate Otilonium Bromide as an NSP15 inhibitor.

• Otilonium Bromide is identified as a quaternary ammonium antimuscarinic compound for research use, with the stated chemical name and salt form reported on the product page product information
• The reported molecular weight is 563.57 g/mol, and the stated purity is at least 98%; these are supplier-reported specifications, and no assay temperature or buffer condition is given on the cited page product information
• The reported solubility is at least 28.18 mg/mL in DMSO, at least 55.8 mg/mL in water, and at least 91 mg/mL in ethanol; the product page does not state the measurement temperature, pH, or equilibration time product information
• The material is recommended for storage at -20°C, and the dossier describes solid powder and 10 mM solution-in-DMSO formats for in vitro workflows product information
• SARS-CoV-2 NSP15 is described as a manganese-dependent nidoviral RNA uridylate-specific endoribonuclease in the cited study; this biochemical mechanism is distinct from muscarinic receptor antagonism Vijayan and Gourinath, 2021
• The study selected thymopentin and oleuropein as top-ranked natural-product candidates after virtual screening and molecular-dynamics analysis; those findings do not constitute evidence for Otilonium Bromide activity Vijayan and Gourinath, 2021

Applications, Limits & Misconceptions

Research applications

Otilonium Bromide can be incorporated into smooth muscle spasm research when investigators need to test the contribution of muscarinic signaling to contraction or relaxation. A tissue or cell model should define the agonist, receptor context, endpoint, and exposure sequence before results are attributed to antimuscarinic activity.

The compound also supports neuroscience receptor modulation experiments. Appropriate endpoints may include agonist-evoked intracellular signaling, neuronal excitability, or transmitter-linked responses. The compound should be paired with receptor-expression data or pharmacological controls when a study makes subtype-level claims.

In a gastrointestinal motility disorder model, Otilonium Bromide may be used as a mechanistic probe for cholinergic contributions to motility-related phenotypes. A model result is not equivalent to clinical efficacy. The product dossier describes in vitro research use and does not establish a treatment recommendation.

Why this cross-domain matters, maturity, and limitations

The supplied reference backbone addresses a different biological target. It describes computational screening against the viral enzyme NSP15 and reports candidate natural products from that screen (reference study). Otilonium Bromide is presented in the product dossier as a muscarinic receptor modulator. These target classes are not interchangeable.

No result in the cited study shows that Otilonium Bromide binds NSP15, inhibits NSP15 catalysis, reduces viral replication, or improves infection outcomes. The antiviral findings should therefore be treated as contextual evidence about target-specific computational screening, not as support for repurposing this antimuscarinic compound. This boundary prevents an unsupported bridge from smooth muscle pharmacology to antiviral therapy.

Common Pitfalls or Misconceptions

1. Assuming broad AChR blockade: The term AChR inhibitor can obscure the distinction between muscarinic and nicotinic receptors. Report the intended muscarinic mechanism explicitly.
2. Interpreting solubility as potency: A supplier-reported solubility value describes formulation capacity under unspecified test conditions. It does not provide an EC50, IC50, receptor affinity, or cellular activity threshold.
3. Using the compound as an established antiviral: The NSP15 paper did not establish Otilonium Bromide as a viral enzyme inhibitor. Do not infer antiviral activity from the paper’s thymopentin or oleuropein results.
4. Ignoring vehicle effects: DMSO can influence cell behavior and assay signals. Match vehicle concentration across control and treatment groups.
5. Conflating in vitro research with clinical use: A reproducible assay result does not establish safety, dosing, or therapeutic efficacy in humans.

Workflow Integration & Parameters

Begin with a formulation check. Select the solid powder when the laboratory prepares fresh stocks under a validated procedure. Select the solution format when a preconfigured 10 mM DMSO stock improves handling consistency. Record lot, formulation, solvent, preparation date, and storage history.

Protocol Parameters

• Stock format: Use the Otilonium Bromide 10 mM solution in DMSO when that format matches the assay plan; the stated concentration refers to the stock solution, not the final treatment concentration product information.
• Storage: Store the material at -20°C as recommended in the product dossier. Protect prepared solutions from unnecessary repeated handling and use them for short-term work only product information.
• Vehicle control: Match DMSO content between treated and control samples. This is a workflow control recommendation rather than a literature-derived dose.
• Concentration conversion: Use 563.57 g/mol for mass-to-molar calculations. State the final concentration, exposure time, temperature, medium, and cell or tissue system in the protocol product information.
• Solubility check: The dossier reports at least 28.18 mg/mL in DMSO, at least 55.8 mg/mL in water, and at least 91 mg/mL in ethanol; because temperature and pH are not specified, verify clarity and precipitation in the actual assay matrix product information.
• Mechanistic readout: Pair a cholinergic stimulus with a receptor-relevant endpoint, such as contractility or intracellular signaling. Include untreated, vehicle, stimulus-only, and antagonist-treated conditions.
• Reproducibility: Use independent biological replicates and define acceptance criteria before unblinding results. Do not substitute supplier solubility for an assay-specific stability study.

For cell-based work, assess morphology and viability alongside the primary signaling endpoint. A decrease in signal can reflect receptor pathway inhibition, cytotoxicity, altered adhesion, or solvent stress. Orthogonal readouts help separate these possibilities. For tissue studies, document tissue source, equilibration conditions, stimulation sequence, and washout procedure.

Related reading

Otilonium Bromide (SKU B1607): Precision in Neuroscience... emphasizes scenario-driven viability, proliferation, and cytotoxicity workflows; this article extends that discussion by separating formulation facts, receptor-level interpretation, and the limits of antiviral extrapolation.

Otilonium Bromide in Neuroscience: Protocols and Optimization focuses on protocols for cholinergic and smooth muscle models; this article clarifies which parameters are supplier-reported and which must be established empirically in each laboratory.

Conclusion & Outlook

Otilonium Bromide is best positioned as an antimuscarinic research tool for controlled studies of cholinergic signaling, smooth muscle function, and related receptor-mediated phenotypes. Its reported molecular weight, purity, solubility profile, storage recommendation, and stock format support practical planning, but assay-specific stability and vehicle controls remain necessary.

The most defensible outlook is better experimental resolution. Future studies can test concentration-response behavior, receptor-context dependence, reversibility, and pathway-selective readouts in defined in vitro systems. The cited NSP15 study remains relevant only as a reminder that computational hits require target-specific validation. It does not support an antiviral role for Otilonium Bromide.